Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Open Access
- 2 April 2012
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 122 (4), 1541-1552
- https://doi.org/10.1172/jci58765
Abstract
Patients with triple-negative breast cancer (TNBC) — defined by lack of estrogen receptor and progesterone receptor expression as well as lack of human epidermal growth factor receptor 2 (HER2) amplification — have a poor prognosis. There is a need for targeted therapies to treat this condition. TNBCs frequently harbor mutations in TP53, resulting in loss of the G1 checkpoint and reliance on checkpoint kinase 1 (Chk1) to arrest cells in response to DNA damage. Previous studies have shown that inhibition of Chk1 in a p53-deficient background in response to DNA damage. We therefore tested whether inhibition of Chk1 could potentiate the cytotoxicity of the DNA damaging agent irinotecan in TNBC using xenotransplant tumor models. Tumor specimens from patients with TNBC were engrafted into humanized mammary fat pads of immunodeficient mice to create 3 independent human-in-mouse TNBC lines: 1 WT (WU-BC3) and 2 mutant for TP53 (WU-BC4 and WU-BC5). These lines were tested for their response to irinotecan and a Chk1 inhibitor (either UCN-01 or AZD7762), either as single agents or in combination. The combination therapy induced checkpoint bypass and apoptosis in WU-BC4 and WU-BC5, but not WU-BC3, tumors. Moreover, combination therapy inhibited tumor growth and prolonged survival of mice bearing the WU-BC4 line, but not the WU-BC3 line. In addition, knockdown of p53 sensitized WU-BC3 tumors to the combination therapy. These results demonstrate that p53 is a major determinant of how TNBCs respond to therapies that combine DNA damage with Chk1 inhibition.This publication has 52 references indexed in Scilit:
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031Journal of Clinical Oncology, 2011
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2010
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJournal of Clinical Oncology, 2009
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA, 2006
- p53 and breast cancer, an updateEndocrine-Related Cancer, 2006
- Chk1 is Essential for Tumor Cell Viability Following Activation of the Replication CheckpointCell Cycle, 2004
- The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast CancerJournal of Clinical Oncology, 2004
- Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functionsOncogene, 1999